1.58
price down icon1.25%   -0.02
after-market After Hours: 1.58
loading
Tiziana Life Sciences Ltd stock is traded at $1.58, with a volume of 376.49K. It is down -1.25% in the last 24 hours and up +16.18% over the past month. Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
See More
Previous Close:
$1.60
Open:
$1.6
24h Volume:
376.49K
Relative Volume:
1.00
Market Cap:
$160.08M
Revenue:
-
Net Income/Loss:
$-13.73M
P/E Ratio:
-12.15
EPS:
-0.13
Net Cash Flow:
$-3.92M
1W Performance:
+1.94%
1M Performance:
+16.18%
6M Performance:
+126.95%
1Y Performance:
+71.93%
1-Day Range:
Value
$1.5299
$1.61
1-Week Range:
Value
$1.5299
$1.81
52-Week Range:
Value
$0.6295
$1.91

Tiziana Life Sciences Ltd Stock (TLSA) Company Profile

Name
Name
Tiziana Life Sciences Ltd
Name
Phone
-
Name
Address
-
Name
Employee
9
Name
Twitter
@tizianals
Name
Next Earnings Date
2024-05-27
Name
Latest SEC Filings
Name
TLSA's Discussions on Twitter

Compare TLSA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
TLSA
Tiziana Life Sciences Ltd
1.58 160.08M 0 -13.73M -3.92M -0.13
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.20 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
525.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
326.09 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
551.22 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
242.07 28.51B 3.81B -644.79M -669.77M -6.24

Tiziana Life Sciences Ltd Stock (TLSA) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-22-20 Initiated B. Riley Securities Buy
Dec-17-18 Initiated Laidlaw Buy

Tiziana Life Sciences Ltd Stock (TLSA) Latest News

pulisher
Jun 16, 2025

Tiziana Life Sciences Ltd (TLSA) Stock: A Year of Stock Market Ups and Downs - investchronicle.com

Jun 16, 2025
pulisher
Jun 16, 2025

Promising Penny Stocks To Consider In June 2025 - simplywall.st

Jun 16, 2025
pulisher
Jun 13, 2025

Tiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis Targeting (NASDAQ:TLSA) - Seeking Alpha

Jun 13, 2025
pulisher
Jun 13, 2025

Tiziana Life Sciences Adds Fifth Site for Phase 2 Foralumab Trial in Multiple Sclerosis - MarketScreener

Jun 13, 2025
pulisher
Jun 13, 2025

Small cap wrap: Tiziana Life Sciences, Challenger Energy, Arrow Exploration... - Proactive financial news

Jun 13, 2025
pulisher
Jun 13, 2025

Tiziana expands Phase 2 MS trial to fifth site, commences patient dosing - Proactive financial news

Jun 13, 2025
pulisher
Jun 13, 2025

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center - The Manila Times

Jun 13, 2025
pulisher
Jun 13, 2025

Breakthrough Multiple Sclerosis Treatment Enters Next Phase as Weill Cornell Joins Major Clinical Trial - Stock Titan

Jun 13, 2025
pulisher
Jun 13, 2025

Market movers: RH, Tiziana, Archer Aviation... - Proactive Investors

Jun 13, 2025
pulisher
Jun 13, 2025

Shares of Tiziana Life Sciences (TLSA) Climb on CEO's Upcoming P - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Tiziana shares rise on presentation date for foralumab data - Seeking Alpha

Jun 13, 2025
pulisher
Jun 13, 2025

Tiziana CEO to present clinical advances of intranasal foralumab at BIO 2025 - Proactive financial news

Jun 13, 2025
pulisher
Jun 13, 2025

Tiziana Life Sciences to Present at the Bio International Convention - The Manila Times

Jun 13, 2025
pulisher
Jun 13, 2025

Revolutionary Intranasal Treatment for MS and Alzheimer's: Tiziana CEO Reveals Latest Clinical Findings at BIO 2025 - Stock Titan

Jun 13, 2025
pulisher
May 27, 2025

Tiziana Life Sciences Ltd (TLSA) Stock: A Comprehensive 52-Week Review - investchronicle.com

May 27, 2025
pulisher
May 27, 2025

Tiziana Life Sciences (NASDAQ:TLSA) Stock Price Up 15.3% – Still a Buy? - Defense World

May 27, 2025
pulisher
May 23, 2025

TLSA Advances Alzheimer's Treatment with Innovative Nasal Spray - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease - marketscreener.com

May 23, 2025
pulisher
May 23, 2025

Tiziana Life Sciences Announces Interview Highlighting Intranasa - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease | TLSA Stock News - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Tiziana Life Sciences Announces Breakthrough Advancement in Moderate Alzheimer’s Treatment with Intranasal Foralumab - Nasdaq

May 23, 2025
pulisher
May 23, 2025

Breakthrough: First Alzheimer's Patient Shows Improvement with Revolutionary Nasal Antibody Treatment - Stock Titan

May 23, 2025
pulisher
May 16, 2025

Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's Disease - BioSpace

May 16, 2025
pulisher
May 16, 2025

Small cap wrap: Lancaster Resources, Cerro de Pasco, Tiziana Life Sciences, Nano One Materials... - Proactive financial news

May 16, 2025
pulisher
May 15, 2025

Tiziana reports reduction in microglial activation in Alzheimer’s case treated with nasal foralumab - Proactive financial news

May 15, 2025
pulisher
May 15, 2025

TLSA: Tiziana Life Sciences Study Shows Promise for Alzheimer's Treatment | TLSA Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Journal of Clinical Nuclear Medicine Publishes Results of Tiziana's Nasal Foralumab in Study Treating Moderate Alzheimer's Disease - The Manila Times

May 15, 2025
pulisher
May 15, 2025

Journal Of Clinical Nuclear Medicine Publishes Results Of Tiziana’S Nasal Foralumab In Study Treating Moderate Alzheimer's Disease - MENAFN.com

May 15, 2025
pulisher
May 15, 2025

Journal of Clinical Nuclear Medicine Publishes Results of - GlobeNewswire

May 15, 2025
pulisher
May 15, 2025

Revolutionary Nasal Treatment Reduces Brain Inflammation in Moderate Alzheimer's Patient, Harvard Study Shows - Stock Titan

May 15, 2025
pulisher
May 12, 2025

Tiziana Life Sciences chairman increases stake to over 37% - Proactive financial news

May 12, 2025
pulisher
May 12, 2025

Executive Chairman Increases Stake in Tiziana Life Sciences (TLS - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Tiziana Life Sciences Announces Purchase of Shares by Chairman - The Manila Times

May 12, 2025
pulisher
May 10, 2025

Tiziana reports promising Alzheimer’s treatment results By Investing.com - Investing.com Nigeria

May 10, 2025
pulisher
May 10, 2025

Tiziana reports promising Alzheimer’s treatment results - Investing.com

May 10, 2025
pulisher
May 09, 2025

Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab - BioSpace

May 09, 2025
pulisher
May 09, 2025

Tiziana Reports PET data sees reduced neuroinflammation in patient treated with Intranasal Therapy - Proactive Investors

May 09, 2025
pulisher
May 09, 2025

Market movers: Lyft, US Gold, Tiziana Life Sciences... - Proactive Investors

May 09, 2025
pulisher
May 09, 2025

Tiziana Life Sciences reports reduced brain inflammation in Alzheimer’s patient treated with nasal foralumab - Proactive Investors

May 09, 2025
pulisher
May 09, 2025

TLSA: Tiziana Life Sciences Reports Positive PET Scan Results in Alzheimer's Treatment | TLSA Stock News - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Tiziana stock gains on data for Alzheimer's drug (TLSA:NASDAQ) - Seeking Alpha

May 09, 2025
pulisher
May 09, 2025

Tiziana Life Sciences Announces Significant Reduction In Microglia Activation In PET Scan Of Moderate Alzheimer's Patient Treated With Intranasal Foralumab - MENAFN.com

May 09, 2025
pulisher
May 09, 2025

Tiziana Life Sciences Announces Significant Reduction in - GlobeNewswire

May 09, 2025
pulisher
May 08, 2025

Tiziana Life Sciences’ intranasal MS candidate shows promise in open-label study - PMLiVE

May 08, 2025
pulisher
May 06, 2025

Small cap wrap: Tiziana Life Sciences, Millennial Potash, Century LIthium... - Proactive financial news

May 06, 2025
pulisher
May 06, 2025

Tiziana shares surge 21% on promising multiple sclerosis data - Proactive financial news

May 06, 2025
pulisher
May 06, 2025

Tiziana rises on positive results in multiple sclerosis treatment study - Seeking Alpha

May 06, 2025
pulisher
May 06, 2025

Tiziana reports encouraging results for nasal MS drug in early study - Proactive Investors

May 06, 2025
pulisher
May 06, 2025

TLSA's Nasal Foralumab Shows Promise in MS Treatment Study | TLS - GuruFocus

May 06, 2025
pulisher
May 06, 2025

TLSA's Nasal Foralumab Shows Promise in MS Treatment Study | TLSA Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Clinical Trial Success: Revolutionary Nasal Spray Halts Multiple Sclerosis Progression in Landmark Study - Stock Titan

May 06, 2025

Tiziana Life Sciences Ltd Stock (TLSA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.66
price up icon 0.78%
$36.03
price up icon 0.45%
$21.28
price up icon 3.30%
$100.64
price up icon 1.16%
$106.47
price down icon 0.23%
biotechnology ONC
$242.07
price up icon 0.36%
Cap:     |  Volume (24h):